Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein

- MOG61-85 represents a cryptic epitope of rMOG in wild-type C57BL/6 mice.
- MOG61-85 is naturally processed in B cell-deficient C57BL/6 mice.
- Immunization with MOG35-55 + MOG61-85 ameliorates clinical EAE in B cell −/− mice
- Processing of MOG61-85 is regulated by an antibody-dependent mechanism

Previous work demonstrated that EAE induced by recombinant human MOG was B cell-dependent. Data presented here reveal a T cell response to MOG61-85 in human rMOG-immunized B cell−/− mice not observed in WT mice. Further study revealed this peptide to be a cryptic epitope in WT mice. Co-immunization of B cell−/− mice with MOG35-55 and MOG61-85 peptides led to less severe disease compared to mice immunized with MOG35-55 alone. Disease amelioration was associated with decreased production of Interferon-γ by lymph node cells. Thus, MOG61-85 represents a protective epitope to human rMOG induced EAE in B cell−/− mice.

163